LitCovid-sample-Enju  

PMC:7205724 / 22333-23259 JSONTXT 23 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T41884 0-5 CD denotes 6.2.2
T3706 7-16 NNP denotes Rationale
T87509 16-17 -COLON- denotes :
T72411 18-29 NNP denotes Tocilizumab
T46139 30-33 MD denotes can
T80638 34-39 VB denotes treat
T14365 40-44 NN denotes lung
T88114 45-51 NN denotes injury
T76208 52-54 IN denotes in
T24628 55-63 NNS denotes patients
T15777 64-68 IN denotes with
T58130 69-77 JJ denotes critical
T31522 78-81 CC denotes and
T55163 82-88 JJ denotes severe
T92225 89-97 NN denotes COVID-19
T21073 98-100 IN denotes In
T65150 101-104 DT denotes the
T61991 105-110 NN denotes study
T18474 111-112 -LRB- denotes [
T8341 112-114 CD denotes 27
T6430 114-115 -RRB- denotes ]
T29393 115-116 -COMMA- denotes ,
T77821 117-119 CD denotes 21
T79215 120-128 NNS denotes patients
T5404 129-133 IN denotes with
T75582 134-142 NN denotes COVID-19
T89299 143-148 WP-DOLLAR- denotes whose
T66055 149-158 NN denotes condition
T80340 159-162 VBD denotes was
T3490 163-169 JJ denotes severe
T44653 170-172 CC denotes or
T55941 173-181 JJ denotes critical
T85453 182-190 VBD denotes received
T98598 191-194 CD denotes one
T96881 195-197 CC denotes or
T24534 198-201 CD denotes two
T70238 202-207 NNS denotes doses
T20616 208-210 IN denotes of
T68912 211-222 NNP denotes Tocilizumab
T98192 223-227 CC denotes plus
T20706 228-236 JJ denotes standard
T58005 237-244 NN denotes therapy
T96625 246-254 NNS denotes Patients
T75572 255-258 WP denotes who
T31917 259-262 VBD denotes had
T15301 263-264 DT denotes a
T24848 265-269 JJ denotes mean
T84688 270-273 NN denotes IL6
T96963 274-279 NN denotes level
T6930 280-282 IN denotes of
T90933 283-287 JJR denotes more
T81944 288-292 IN denotes than
T75581 293-302 NN denotes 100 pg/ml
T64021 303-309 IN denotes before
T9387 310-321 NN denotes tocilizumab
T84664 322-331 NN denotes treatment
T18203 332-338 VBD denotes showed
T60803 339-350 NN denotes improvement
T44490 351-353 IN denotes in
T81402 354-362 JJ denotes clinical
T14228 363-371 NNS denotes symptoms
T94537 372-375 CC denotes and
T83697 376-386 JJ denotes peripheral
T13978 387-393 NN denotes oxygen
T35808 394-404 NN denotes saturation
T34900 405-408 CC denotes and
T75964 409-422 NN denotes normalization
T84268 423-426 IN denotes for
T65028 427-437 NN denotes lymphocyte
T34390 438-448 NN denotes proportion
T96610 449-452 CC denotes and
T30755 453-456 NN denotes CRP
T63070 457-463 NNS denotes levels
T31791 465-469 RB denotes Also
T31152 469-470 -COMMA- denotes ,
T79595 471-475 NN denotes lung
T51431 476-482 NN denotes lesion
T10130 483-490 NN denotes opacity
T31388 491-494 VBD denotes was
T1824 495-503 VBN denotes absorbed
T60055 504-506 IN denotes in
T38598 507-509 CD denotes 90
T67288 509-510 NN denotes %
T48683 511-513 IN denotes of
T41529 514-522 NNS denotes patients
T69670 524-531 CC denotes Neither
T9277 532-539 JJ denotes serious
T15021 540-547 JJ denotes adverse
T23626 548-555 NNS denotes effects
T98539 556-559 CC denotes nor
T65699 560-566 NNS denotes deaths
T50204 567-575 VBD denotes occurred
T20973 576-580 IN denotes with
T14012 581-592 NN denotes tocilizumab
T66286 593-602 NN denotes treatment
T24269 604-609 EX denotes There
T26765 610-613 VBP denotes are
T84711 614-621 VBG denotes ongoing
T74304 622-630 JJ denotes clinical
T68003 631-637 NNS denotes trials
T5000 638-641 IN denotes for
T64198 642-653 NN denotes tocilizumab
T83078 654-663 NN denotes treatment
T11331 664-666 IN denotes in
T42834 667-675 NNS denotes patients
T27205 676-680 IN denotes with
T23786 681-689 JJ denotes moderate
T45333 690-693 CC denotes and
T9137 694-700 JJ denotes severe
T27842 701-709 NN denotes COVID-19
T92236 711-720 RB denotes Currently
T32112 720-721 -COMMA- denotes ,
T54987 722-725 DT denotes the
T85855 726-729 NN denotes use
T69355 730-732 IN denotes of
T40115 733-744 NNP denotes Tocilizumab
T10850 745-747 VBZ denotes is
T78367 748-759 VBN denotes recommended
T33042 760-763 IN denotes for
T36466 764-772 NNS denotes patients
T61983 773-777 IN denotes with
T2749 778-786 NN denotes COVID-19
T17580 787-790 WP denotes who
T69055 791-795 VBP denotes have
T71996 796-803 VBG denotes warning
T59356 804-809 NNS denotes signs
T65527 810-812 IN denotes of
T99769 813-818 NN denotes hyper
T44301 819-831 NN denotes inflammation
T54453 831-832 -COMMA- denotes ,
T58078 833-835 IN denotes as
T75237 836-839 MD denotes can
T7496 840-842 VB denotes be
T53845 843-851 VBN denotes measured
T78207 852-854 IN denotes by
T88455 855-858 NN denotes IL6
T77671 858-859 -COMMA- denotes ,
T67481 860-868 NN denotes ferritin
T99390 868-869 -COMMA- denotes ,
T23484 870-878 NN denotes platelet
T65701 879-885 NNS denotes counts
T30323 885-886 -COMMA- denotes ,
T72053 887-899 JJ denotes inflammatory
T81575 900-907 NNS denotes markers
T96428 907-908 -COMMA- denotes ,
T36542 909-912 CC denotes and
T88469 913-914 NN denotes H
T51141 915-920 NN denotes score
T97739 921-922 -LRB- denotes [
T29313 922-924 CD denotes 28
T54016 924-925 -RRB- denotes ]
R10896 T63070 T65028 arg1Of levels,lymphocyte
R12091 T60803 T44490 arg1Of improvement,in
R13130 T30755 T96610 arg2Of CRP,and
R13154 T85855 T7496 arg1Of use,be
R13264 T44301 T99769 arg1Of inflammation,hyper
R14004 T66055 T89299 arg1Of condition,whose
R15083 T36542 T96428 arg1Of and,","
R15531 T77671 T99390 arg1Of ",",","
R16905 T68003 T84711 arg1Of trials,ongoing
R17601 T27842 T27205 arg2Of COVID-19,with
R19206 T53845 T78207 arg1Of measured,by
R20598 T55163 T31522 arg2Of severe,and
R21368 T24628 T15777 arg1Of patients,with
R21619 T34900 T94537 arg2Of and,and
R21977 T81575 T30323 arg2Of markers,","
R22400 T44301 T65527 arg2Of inflammation,of
R22449 T98539 T69670 arg1Of nor,Neither
R2282 T67481 T77671 arg2Of ferritin,","
R24887 T35808 T13978 arg1Of saturation,oxygen
R25403 T3490 T44653 arg1Of severe,or
R26554 T83078 T5000 arg2Of treatment,for
R26904 T85855 T78367 arg2Of use,recommended
R27191 T23626 T98539 arg1Of effects,nor
R27294 T1824 T31388 arg2Of absorbed,was
R27449 T83078 T64198 arg1Of treatment,tocilizumab
R27501 T51141 T36542 arg2Of score,and
R27739 T61991 T21073 arg2Of study,In
R28465 T23786 T45333 arg1Of moderate,and
R29264 T44653 T80340 arg2Of or,was
R29518 T68003 T5000 arg1Of trials,for
R29604 T88114 T80638 arg2Of injury,treat
R30062 T42834 T27205 arg1Of patients,with
R3039 T79215 T5404 arg1Of patients,with
R31375 T75582 T5404 arg2Of COVID-19,with
R34037 T68003 T74304 arg1Of trials,clinical
R35135 T36466 T69055 arg1Of patients,have
R37231 T98539 T50204 arg1Of nor,occurred
R37530 T80638 T46139 arg2Of treat,can
R37793 T96625 T75572 arg1Of Patients,who
R40933 T36542 T78207 arg2Of and,by
R41615 T51141 T97739 arg1Of score,[
R42123 T70238 T85453 arg2Of doses,received
R42879 T98539 T9277 arg1Of nor,serious
R4477 T92225 T55163 arg1Of COVID-19,severe
R44975 T10130 T1824 arg2Of opacity,absorbed
R45661 T90933 T64021 arg1Of more,before
R48681 T61991 T18474 arg1Of study,[
R48731 T59356 T69055 arg2Of signs,have
R4907 T85855 T10850 arg1Of use,is
R49421 T1824 T60055 arg1Of absorbed,in
R50965 T66286 T14012 arg1Of treatment,tocilizumab
R51850 T94537 T18203 arg2Of and,showed
R52999 T66055 T80340 arg1Of condition,was
R53041 T58078 T92236 arg1Of as,Currently
R53068 T96963 T31917 arg2Of level,had
R53187 T96963 T24848 arg1Of level,mean
R5373 T90933 T6930 arg2Of more,of
R53734 T24534 T96881 arg2Of two,or
R54223 T78367 T10850 arg2Of recommended,is
R5554 T60803 T94537 arg1Of improvement,and
R56159 T50204 T20973 arg1Of occurred,with
R56743 T98192 T20616 arg2Of plus,of
R57258 T90933 T81944 arg1Of more,than
R5731 T70238 T24534 arg1Of doses,two
R57903 T63070 T34390 arg1Of levels,proportion
R59110 T29313 T97739 arg2Of 28,[
R59576 T9137 T45333 arg2Of severe,and
R60119 T36466 T17580 arg1Of patients,who
R60586 T65701 T99390 arg2Of counts,","
R61251 T2749 T61983 arg2Of COVID-19,with
R61440 T58005 T98192 arg2Of therapy,plus
R61441 T58078 T32112 arg1Of as,","
R6154 T59356 T65527 arg1Of signs,of
R61551 T14228 T81402 arg1Of symptoms,clinical
R62752 T34900 T84268 arg1Of and,for
R64318 T65699 T98539 arg2Of deaths,nor
R65601 T70238 T20616 arg1Of doses,of
R66809 T14228 T44490 arg2Of symptoms,in
R66943 T85855 T54987 arg1Of use,the
R66954 T24269 T26765 arg1Of There,are
R67132 T70238 T98598 arg1Of doses,one
R67692 T75964 T34900 arg2Of normalization,and
R68271 T30323 T36542 arg1Of ",",and
R69456 T24628 T76208 arg2Of patients,in
R71674 T85855 T75237 arg1Of use,can
R72772 T59356 T71996 arg1Of signs,warning
R72983 T78367 T54453 arg1Of recommended,","
R74424 T98598 T96881 arg1Of one,or
R74963 T79215 T85453 arg1Of patients,received
R75326 T85453 T21073 arg1Of received,In
R75826 T96963 T15301 arg1Of level,a
R76104 T41529 T48683 arg2Of patients,of
R76550 T58130 T31522 arg1Of critical,and
R76769 T92225 T58130 arg1Of COVID-19,critical
R77316 T54016 T97739 arg3Of ],[
R78022 T66055 T55941 arg1Of condition,critical
R78533 T42834 T11331 arg2Of patients,in
R78642 T84664 T9387 arg1Of treatment,tocilizumab
R79228 T79215 T77821 arg1Of patients,21
R79687 T92225 T15777 arg2Of COVID-19,with
R79916 T84664 T64021 arg2Of treatment,before
R79941 T66286 T20973 arg2Of treatment,with
R80450 T8341 T18474 arg2Of 27,[
R81194 T55941 T44653 arg2Of critical,or
R8185 T96625 T18203 arg1Of Patients,showed
R81985 T1824 T31791 arg1Of absorbed,Also
R8244 T63070 T84268 arg2Of levels,for
R82985 T80638 T76208 arg1Of treat,in
R82994 T61991 T65150 arg1Of study,the
R83390 T51141 T88469 arg1Of score,H
R84172 T75582 T89299 arg2Of COVID-19,whose
R84332 T3706 T87509 arg1Of Rationale,:
R84932 T53845 T7496 arg2Of measured,be
R85183 T98539 T15021 arg1Of nor,adverse
R85482 T78367 T58078 arg1Of recommended,as
R85705 T67288 T38598 arg1Of %,90
R86004 T72411 T46139 arg1Of Tocilizumab,can
R87538 T85855 T53845 arg2Of use,measured
R88261 T96963 T84688 arg1Of level,IL6
R88299 T63070 T30755 arg1Of levels,CRP
R89076 T88455 T77671 arg1Of IL6,","
R89241 T27842 T23786 arg1Of COVID-19,moderate
R89881 T85855 T69355 arg1Of use,of
R89899 T68912 T98192 arg1Of Tocilizumab,plus
R8993 T65701 T23484 arg1Of counts,platelet
R89954 T67288 T60055 arg2Of %,in
R9002 T3706 T41884 arg1Of Rationale,6.2.2
R90450 T10130 T31388 arg1Of opacity,was
R90482 T88114 T14365 arg1Of injury,lung
R90654 T66055 T3490 arg1Of condition,severe
R90774 T35808 T34900 arg1Of saturation,and
R90910 T1824 T31152 arg1Of absorbed,","
R91084 T67288 T48683 arg1Of %,of
R91228 T96625 T31917 arg1Of Patients,had
R92122 T81575 T72053 arg1Of markers,inflammatory
R92198 T72411 T80638 arg1Of Tocilizumab,treat
R92393 T35808 T83697 arg1Of saturation,peripheral
R92489 T40115 T69355 arg2Of Tocilizumab,of
R92565 T99390 T30323 arg1Of ",",","
R92720 T36466 T61983 arg1Of patients,with
R93944 T78367 T33042 arg1Of recommended,for
R94262 T68003 T26765 arg2Of trials,are
R94310 T53845 T58078 arg2Of measured,as
R94369 T75581 T81944 arg2Of 100 pg/ml,than
R95470 T83078 T11331 arg1Of treatment,in
R96088 T96963 T6930 arg1Of level,of
R96842 T53845 T75237 arg2Of measured,can
R96954 T36466 T33042 arg2Of patients,for
R97104 T27842 T9137 arg1Of COVID-19,severe
R97168 T34390 T96610 arg1Of proportion,and
R97353 T58005 T20706 arg1Of therapy,standard
R98220 T85453 T29393 arg1Of received,","
R9904 T10130 T51431 arg1Of opacity,lesion
R99138 T10130 T79595 arg1Of opacity,lung
R99891 T6430 T18474 arg3Of ],[